Genotypic Technology Pvt. Ltd. is a genomics solution provider offering Next Generation Sequencing (NGS), Microarray, and Bioinformatics services, solutions, and products. It serves domestic and international pharmaceutical, biotech companies, and academia.

Genotypic Technology Pvt. Ltd.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Ben Hindson

Serge Saxonov

10x Genomics, Inc.

Dhiti Omics provides precision molecular diagnostics and genetic testing services to aid in understanding the genetic basis of disease and its prognosis. The company employs a range of genomics technologies, including Microarray and Next Generation Sequencing, to decode genetic variants.

Metric
Company Name	Genotypic Technology Pvt. Ltd.	10	Dhiti Omics
Symbol		TXG
MSH ID	IN:CO:GENOTYPIC	COM:10XGENOMICS	COM:DHITIOMICS
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Medical - Healthcare Information Services	Biotechnology
Country	IN	US	IN
Stage		Post-IPO
Employee Count		1.26K
Website	genotypic.co.in	10xgenomics.com	dhitiomics.com
LinkedIn		10xgenomics
Founders

Metric
Market Cap		1.88B
Enterprise Value
Monthly Web Traffic		150.48K
Web Traffic Growth		-0.39
Valuation
Raised Capital

Metric
Revenue		618.73M
Revenue (LTM)
Revenue (NTM)
Gross Profit		409.31M
EBITDA		-158.25M
Operating Income		-201.87M
Net Income		-255.10M
EPS		-2.18
Diluted EPS		-2.18
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.65
Operating Profit Margin		-0.37
EBITDA Margin		-0.26
Net Profit Margin		-0.38
Return on Equity		-0.33
Return on Assets		-0.26
Return on Capital Employed		-0.28

CO

IN:CO:GENOTYPIC

Genotypic Technology Pvt. Ltd.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-22.67
P/B Ratio		6.79
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		7.04
EV Multiple		-9.56

Metric
Days Sales Outstanding		64.14
Days Payables Outstanding		38.61
Days Inventory Outstanding		141.51
Operating Cycle		194.20
Cash Conversion Cycle		164.30
Asset Turnover		0.68

Metric
Operating Cash Flow		-15.20M
Free Cash Flow		-64.72M
Cash Flow to Debt		-0.09
Operating Cash Flow/Sales		-0.01
Free Cash Flow Yield		-0.02

Metric
Cash & Equivalents		359.28M
Accounts Receivable		-10.61M
Inventory		73.71M
Goodwill		4.51M
Debt to Capitalization		0.11
Debt to Assets		0.10
Current Ratio		5.37
Quick Ratio		4.45

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.29
R&D to Revenue		0.52
SG&A to Revenue